抗体与新型冠状病毒2：诊断与治疗的新数据。
Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics.
作者信息
Focosi Daniele, Franchini Massimo
机构信息
North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.
Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, 46100 Mantova, Italy.
出版信息
Life (Basel). 2022 Apr 20;12(5):614. doi: 10.3390/life12050614.
Abstract
Welcome to the Special Issue of entitled [...].
摘要
欢迎阅读名为《[...]》的特刊。
相似文献
1
Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics.抗体与新型冠状病毒2：诊断与治疗的新数据。
Life (Basel). 2022 Apr 20;12(5):614. doi: 10.3390/life12050614.
2
Evaluation of Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate Virus Neutralization Test.评估感染和接种疫苗后针对 SARS-CoV-2 变异体的中和抗体：使用多重假病毒中和试验。
Clin Chem. 2022 May 18;68(5):702-712. doi: 10.1093/clinchem/hvab283.
3
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.康复者中 SARS-CoV-2 感染的性别差异和中和抗体持久性。
mSphere. 2021 Aug 25;6(4):e0027521. doi: 10.1128/mSphere.00275-21.
4
Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively.一种用于半定量识别 COVID-19 患者 S1/S2 中和 IgG 的自动化血清学检测的临床和分析性能。
J Clin Microbiol. 2020 Aug 24;58(9). doi: 10.1128/JCM.01224-20.
5
Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.etesevimab 联合 JS026 中和 SARS-CoV-2 及其变体。
Emerg Microbes Infect. 2022 Dec;11(1):548-551. doi: 10.1080/22221751.2022.2032374.
6
COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.COVID-19 严重程度与抗体 Fc 介导的固有免疫功能的差异有关。
mBio. 2021 Apr 20;12(2):e00281-21. doi: 10.1128/mBio.00281-21.
7
Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.COVID-19 患者体内针对 SARS-CoV-2 的中和抗体反应。
Indian J Med Res. 2020;152(1 & 2):82-87. doi: 10.4103/ijmr.IJMR_2382_20.
8
Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.适体BC 007对特异性和非特异性抗SARS-CoV-2中和抗体的亲和力。
Viruses. 2021 May 18;13(5):932. doi: 10.3390/v13050932.
9
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.针对 SARS-CoV-2 刺突受体结合域和核衣壳的异源抗体及其对 COVID-19 免疫的影响。
JCI Insight. 2020 Sep 17;5(18):142386. doi: 10.1172/jci.insight.142386.
10
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.高通量单细胞测序鉴定恢复期患者 B 细胞中的 SARS-CoV-2 强效中和抗体。
Cell. 2020 Jul 9;182(1):73-84.e16. doi: 10.1016/j.cell.2020.05.025. Epub 2020 May 18.
本文引用的文献
1
Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2.使用定量干血斑评估接种疫苗后针对 SARS-CoV-2 的中和抗体水平。
Life (Basel). 2021 Oct 22;11(11):1125. doi: 10.3390/life11111125.
2
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的出现及恢复期血浆疗法在感染管理中的作用
Life (Basel). 2021 Jul 23;11(8):734. doi: 10.3390/life11080734.
3
The Three Pillars of COVID-19 Convalescent Plasma Therapy.新冠康复者血浆治疗的三大支柱
Life (Basel). 2021 Apr 18;11(4):354. doi: 10.3390/life11040354.
4
Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and Suggests Original Antigenic Sin.既往对地方性季节性甲型冠状病毒NL63和229E的体液免疫与COVID-19更差的临床结局相关，并提示存在原始抗原ic原罪。
Life (Basel). 2021 Apr 1;11(4):298. doi: 10.3390/life11040298.
5
Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series.一组波兰新冠病毒肺炎儿科患者接受恢复期血浆治疗的疗效与安全性：病例系列报告
Life (Basel). 2021 Mar 17;11(3):247. doi: 10.3390/life11030247.
Zotero 插件